Johnson & Johnson plans to conduct a late-stage study of the company’s investigational vaccine for Human Immunodeficiency Virus (HIV) in several countries across the Americas and Europe, including the United States.
Teva Pharmaceutical agreed to pay an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that the world’s largest generic manufacturer and other drugmakers helped fuel the U.S. opioid epidemic.
Maine became the 25th U.S. state to confirm a case of measles amid the country’s worst outbreak of the disease in a quarter century.
Five U.S. states filed lawsuits accusing Purdue Pharma LP of illegally marketing and selling opioids, including OxyContin.
With the acquisition of Shire, Takeda Pharmaceutical is building up the company’s research and development presence in the United States. Additionally, Insulet Corporation is celebrating the grand opening of the company’s new global headquarters and U.S. manufacturing facility in Acton, Mass.
Maine could soon prohibit parents from citing religious or personal beliefs to avoid vaccinating their children, making the U.S. state one of a half dozen cracking down during the nations’ largest measles outbreak in 25 years.
Drug distributor McKesson Corp. agreed to pay $37 million to resolve a lawsuit by the state of West Virginia seeking to hold the company responsible for contributing to the opioid epidemic, the state’s attorney general said.
GlaxoSmithKline is investing heavily in a Montana manufacturing facility that specializes in the manufacture of the company’s two-year-old shingles vaccine Shingrix, which is eying blockbuster status.
Gilead Sciences subsidiary Kite Pharma broke ground on a Maryland facility that will significantly expand the company’s ability to manufacture a variety of CAR-T therapies, including the company’s previously approved Yescarta.
Roche lifted the Swiss drugmaker’s 2019 outlook as sales growth in China and the United States outpaced price declines the company has suffered amid President Donald Trump’s pressure on the industry to hold down charges.